SSRI Antidepressants Trigger Fear And Anxiety, Study Finds
Oct 2, 2016
University of North Carolina Health Care
More than 100 million people worldwide take selective serotonin reuptake inhibitors (SSRIs), such as Prozac, Zoloft, Lexapro, and Paxil, to treat depression, anxiety, and related conditions. But these drugs have a common side effect: they can worsen fear and anxiety.
Scientists at the University of North Carolina (UNC) School of Medicine have mapped out a serotonin-driven anxiety circuit that may explain this side effect and lead to treatments to eliminate it.
"The hope is that we'll be able to identify a drug that inhibits this circuit," said senior investigator Thomas L. Kash, PhD, the John Andrews Distinguished Professor of Alcohol Studies in the UNC School of Medicine's department of pharmacology. "More generally, this finding gives us a deeper understanding of the brain networks that drive anxiety and fear behavior in mammals."
The new study, published in Nature, counters the popular view of serotonin as a neurotransmitter that promotes only good feelings. SSRIs, which are taken by about one in 10 people in the United States and about one in four women in their 40s and 50s, are thought to improve mood by boosting serotonin activity in the brain. There are brain circuits through which serotonin does seem to improve mood, and some studies have linked depression to abnormally low levels of serotonin. But the short-lived promotion of anxiety in many patients on SSRIs - even suicidal thinking, particularly in younger people - has long hinted that serotonin can have negative effects on mood, depending on the precise brain circuit where it acts.
In the Nature study, for which co-authors were UNC postdoctoral researcher Catherine A. Marcinkiewcz, PhD, and UNC graduate student Christopher M. Mazzone, the researchers used an array of sophisticated methods, including advanced optogenetic and chemogenetic tools, to trace a serotonin-activated pathway in the brains of mice, a pathway that drives anxious behavior.
The team first demonstrated that a mild shock to the paws of mice - a standard method for evoking fear and anxiety behaviors - activates serotonin-producing neurons in the dorsal raphe nucleus (DRN), a brainstem region known to be involved in mood and depression. These DRN serotonin neurons project to a brain region that is called the bed nucleus of the stria terminalis (BNST) and has been shown in previous studies to have a role in serotonin's negative mood effects in rodents. Artificially increasing the activity of the DRN-to-BNST neurons enhanced anxiety-like behaviors in the mice.
UNC scientists found that the serotonin output from the DRN neurons activates their target neurons in the BNST through a specific subset of serotonin receptors, known as 2C receptors. These serotonin-activated BNST neurons then tamp down the activity of another family of BNST neurons, which, in turn, project to the ventral tegmental area (VTA) and lateral hypothalamus (LH) - key nodes in the brain's reward, motivation and alertness networks.
The pathways from BNST to VTA and LH have been reported in previous studies to improve mood and relieve anxiety. Researchers confirmed that artificially driving the activity of these pathways has the effect of reducing foot-shock-induced fear and anxiety behaviors in the mice. By contrast, the silencing of these pathways by serotonin-activated BNST neurons effectively allows the anxiety level to rise.
Examining the impact of SSRIs, the scientists exposed 2C-receptor BNST neurons to fluoxetine (Prozac), which like other SSRIs gives a boost to serotonin levels wherever the neurotransmitter is at work. This turned out to increase the 2C-receptor neurons' inhibitory effect on the neighboring VTA- and LH-projecting neurons, worsening fear and anxiety behavior in mice.
The next step is to find out how this negative effect could be blocked. To that end, the researchers had some ideas. Kash and his team observed that the anxiety-mediating BNST neurons expressed the stress-signaling molecule corticotropin releasing factor (CRF). When they added a compound to block CRF activity, they witnessed that fearful behaviors - which had been triggered by fluoxetine - were greatly reduced.
Based on this observation in mice, one of the next steps is to confirm that this serotonin-sensitive DRN-to-BNST anxiety circuit exists in humans as well. "It's logical that it would," Kash said, "since we know SSRIs can induce anxiety in people, and the pathways in these brain regions tend to be very similar in mice and humans."
Another next step will be to test drugs - ideally FDA-approved for various conditions - for their ability to alter this anxiety circuit and thereby block SSRIs' anxiety-inducing effect. In principle, a CRF-blocker might work. For years, pharmaceutical companies have been trying to develop CRF blockers to treat depression, anxiety and addiction. In practice, Kash said, CRF blockers haven't yet had success in clinical trials, so an FDA-approved one is probably still years away at least.
"Other researchers are working to develop better CRF-inhibiting compounds, so that's one potential direction to take, but there are others," Kash said. "We're now looking at the various proteins expressed by these BNST neurons, and we're hoping to identify a receptor that is already targeted by established drugs.”
A common problem with medication, especially psychotropic medications, is that all medications produce side effects. The challenge then is to find another medication that potentially reduces those side effects. But his second medication can also produce side effects, which may require another medication to mitigate, and so on. Consequently, it’s common for a person to be on a cocktail of medications all trying to solve one problem.
It’s our experience that while SSRI medications may help reduce symptoms for some people (approximately one third of people who take them), they don’t correct the cause of the problem, which is unhealthy behavior. Only when the unhealthy behavior is identified and successfully addressed will anxiety and/or depression symptoms be successfully relieved. When you resolve the problem, the problem and its symptoms disappear.
This is why medication should never be considered a cure for anxiety and/or depression. Medication does not correct unhealthy behavior. Medication can only manage symptoms for some people - research has found that only one third of those who take SSRI antidepressant medications experience some sort of symptom relief, whereas one third experience no benefit and one third experience a worsening of symptoms.
For more information about the cause of anxiety, see our Anxiety 101 section.
Disclaimer: anxietycentre.com is not responsible for the accuracy of news releases posted at anxietycentre.com by contributing institutions or for the use of any information throughout anxietycentre.com's system.
The combination of good self-help information and working with an experienced anxiety disorder coach, counselor, or therapist is the most effective way to address anxiety disorder and its many symptoms. Until the core causes of anxiety are addressed - the underlying factors that motivate apprehensive behavior - a struggle with anxiety disorder can return again and again. Identifying and successfully addressing anxiety's underlying factors is the best way to overcome problematic anxiety.
For more information about our Anxiety Counseling option; our Available Anxiety Therapists; to Book An Appointment with one of our anxiety therapists; common Anxiety Signs and Symptoms; common Anxiety Attack Symptoms; the symptoms of panic attack disorder; anxiety Recovery Support area; information about Anxiety; and our Anxiety 101 section; or click on the appropriate link or graphic below:
Return to our anxiety research page.
Authors: Jim Folk, Marilyn Folk, BScN. Last updated November 20, 2018.